The overall objectives of this project are to understand the functional importance of orbital fibroblast heterogeneity and to define the role of the CD40/CD154 fibroblast activational bridge in the pathogenesis of thyroid associated ophthalmopathy (TAO). The hypothesis to be tested is that the orbit is susceptible to tissue remodeling in TAO because of unique fibroblast phenotypes and because TAO fibroblasts, unexpectedly, express both CD40 and its cognate ligand, CD154. When CD40 on orbital fibroblasts is ligated with CD154, down-stream genes are activated, leading to the disordered production of PGE2 and hyaluronan. Orbital fibroblasts, divided into subsets on the basis of Thy-1 expression, exhibit substantially different phenotypes. Thy-1- fibroblasts, when activated, express high levels of IL-8 and represent pre-adipocytes that can differentiate in vitro into adipocytes. Thy-1+ fibroblasts, when treated with IgG from patients with Graves' disease, produce extraordinarily high levels of IL-16, a CD4+ lymphocyte specific chemoattractant, and RANTES, a c-c chemokine. This activity is apparently mediated though the IGF-1 receptor. The applicant hypothesizes that these latter inductions, limited to the Thy1+ subset, represent the basis for lymphocyte infiltration of the orbit in TAO. We now propose to 1) define the role of the CD40/CD154 bridge in the activation of orbital fibroblasts by characterizing CD40 and CD154 expression and signaling to down-stream responses; 2) compare inflammatory phenotypes exhibited by Thy-1+ and Thy-1- orbital fibroblasts by determining whether Thy-1 cross-linking results in fibroblast activation and determining the molecular basis for IGF-1 receptor involvement in the IL-16 and RANTES inductions; 3) define the inflammatory phenotype of adipocytes differentiated in vitro from Thy-1- orbital fibroblasts. We believe that the results of the proposed studies will lead to important insights concerning the pathogenesis of TAO and potentially define therapeutic targets for interrupting this disease.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Research Project (R01)
Project #
5R01EY011708-08
Application #
6625688
Study Section
Visual Sciences A Study Section (VISA)
Program Officer
Hunter, Chyren
Project Start
1997-04-01
Project End
2007-03-31
Budget Start
2003-04-01
Budget End
2004-03-31
Support Year
8
Fiscal Year
2003
Total Cost
$354,337
Indirect Cost
Name
La Biomed Research Institute/ Harbor UCLA Medical Center
Department
Type
DUNS #
069926962
City
Torrance
State
CA
Country
United States
Zip Code
90502
Smith, Terry J (2018) Challenges in Orphan Drug Development: Identification of Effective Therapy for Thyroid-Associated Ophthalmopathy. Annu Rev Pharmacol Toxicol :
Smith, Terry J; Kahaly, George J; Ezra, Daniel G et al. (2017) Teprotumumab for Thyroid-Associated Ophthalmopathy. N Engl J Med 376:1748-1761
Chen, Hong; Shan, Shannon J C; Mester, Tünde et al. (2015) TSH-Mediated TNF? Production in Human Fibrocytes Is Inhibited by Teprotumumab, an IGF-1R Antagonist. PLoS One 10:e0130322
Lee, Brian J; Atkins, Stephen; Ginter, Anna et al. (2015) Increased CD40+ Fibrocytes in Patients With Idiopathic Orbital Inflammation. Ophthal Plast Reconstr Surg 31:202-6
Stein, Joshua D; Childers, David; Gupta, Shivani et al. (2015) Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease. JAMA Ophthalmol 133:290-6
Kristensen, Birte; Hegedüs, Laszlo; Lundy, Steven K et al. (2015) Characterization of Regulatory B Cells in Graves' Disease and Hashimoto's Thyroiditis. PLoS One 10:e0127949
Kristensen, B; Hegedüs, L; Madsen, H O et al. (2015) Altered balance between self-reactive T helper (Th)17 cells and Th10 cells and between full-length forkhead box protein 3 (FoxP3) and FoxP3 splice variants in Hashimoto's thyroiditis. Clin Exp Immunol 180:58-69
Douglas, Raymond S; Mester, Tünde; Ginter, Anna et al. (2014) Thyrotropin receptor and CD40 mediate interleukin-8 expression in fibrocytes: implications for thyroid-associated ophthalmopathy (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 112:26-37
McCoy, Allison N; Kim, Denise S; Gillespie, Erin F et al. (2014) Rituximab (Rituxan) therapy for severe thyroid-associated ophthalmopathy diminishes IGF-1R(+) T cells. J Clin Endocrinol Metab 99:E1294-9
Wang, Yao; Smith, Terry J (2014) Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy. Invest Ophthalmol Vis Sci 55:1735-48

Showing the most recent 10 out of 102 publications